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Lung cancer is one type of cancer for which treatment has been “personalized” through the use of specific protein tyrosine kinase inhibitors. Several genes encoding protein 
kinases have been identified as driver oncogenes in lung adenocarcinoma, the most fre-
quent histological type of lung cancer. The activating aberrations of these genes that drive 
carcinogenesis include EGFR mutations, ALK fusions, ROS1 fusions, and RET fusions. 
These aberrations cause oncogenic addiction in cancer cells; this phenomenon makes the 
aberrations a therapeutic target for tyrosine kinase inhibitors and has been validated in 
genetically engineered mouse models (GEMMs) in which oncogene activation is artificially 
reproduced in the lungs (Table 1). Interestingly, secondary genetic aberrations have been 
detected in GEMM tumors as in human lung adenocarcinoma.1 Therefore, GEMMs are 
useful for understanding the carcinogenic processes and for identifying potential diagnostic 
and treatment seeds.
In this issue, Dr. Gazdar et al. report a pathological study of tumors in five GEMMs 
that mirror the development of small-cell lung cancer (SCLC), the most aggressive type 
of lung cancer, which shows neuroendocrine features.2 Because SCLC metastasizes and 
disseminates at an early stage, only a small subset of patients are eligible for surgical resec-
tion with curative intent. Therefore, the number of tumor specimens available for large-
scale Omics analysis is very limited, and only a few studies have performed genome-wide 
analysis of the genetic aberrations underlying SCLC.3–6 Unfortunately, to date, druggable 
genetic alterations, such as FGFR1 amplification and PTEN/PIK3CA alterations, have been 
detected in only a small subset of cases, thereby preventing us from developing a personal-
ized medicine approach to SCLC.
Notably, however, observation of human SCLC has led to the generation of five 
GEMMs, in which well-known tumor suppressor genes, TP53 and RB1 (and others), have 
been engineered to be inactivated in the lung.3–6 Distinguished pathologists from differ-
ent institutions performed a detailed and uniform pathological analysis of the resulting 
lung tumors that developed in those GEMMs. The authors found that these GEMMs were 
extremely useful for studying human SCLC. The GEMM tumors generated by these engi-
neered genetic aberrations display definite characteristics of SCLC and, as such, will aid 
future research by compensating for the shortage of human SCLC samples. Future com-
prehensive Omics analysis of these GEMM tumors should identify genes, pathways, and 
molecules worthy of further study.
Thus, comparative studies of human and mouse lung tumors will facilitate the pre-
vention, diagnosis, and treatment of the deadliest type of lung cancer.
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TABLE 1.  Genetically Engineered Mouse Models of Lung Adenoma and Adenocarcinoma
Driver Oncogene Genetic Aberration Introduced Molecular Targeting Drugs Tested References
KRAS G12D mutation Jackson et al. (2001), Johnson et al. (2001)
EGFR ΔL747–S752 mutation, L858R mutation Erlotinib, cetuximab Politi et al. (2006), Ji et al. (2006)
BRAF V600E mutation PD0325901, PD184352 (MEK inhibitors) Dankort et al. (2007), Ji et al. (2007)
HER2 YVMA insertion mutation Afatinib Perera et al. (2009)
ALK EML4-ALK fusion 2,4-pyrimidinediamine derivative (ALK inhibitor) Soda et al. (2008)
ROS1 EZR-ROS1 fusion Crizotinib Arai et al. (2013)
RET KIF5B-RET fusion Vandetanib Saito et al. (2014)
